Literature DB >> 26853179

Keratoacanthoma (KA): An update and review.

Bartlomiej Kwiek1, Robert A Schwartz2.   

Abstract

Keratoacanthoma (KA) is a common but underreported tumor of the skin. Two striking features of KA are its clinical behavior with spontaneous regression after rapid growth and its nosological position on the border between benignity and malignancy. We review current knowledge on the clinical, histopathological, and dermoscopic features of KA to ensure a proper diagnosis and describe its variants, including different types of multiple KAs. We highlight current concepts of KA ethiopathogenesis with special emphasis on the genetic background of multiple familial KA, the role of Wnt signaling pathway, and induction of KA by BRAF inhibitors and procedures of esthetic dermatology. Finally, treatment strategies are presented with surgical excision as a first option, followed by other modalities, including intralesional chemotherapy, topical and systemic agents, lasers, cryotherapy, and photodynamic therapy.
Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRAF inhibitor; Ferguson-Smith; Grzybowski; erlotinib; histopathology; keratoacanthoma; multiple keratoacanthoma; multiple self-healing squamous epithelioma; squamous cell carcinoma; treatment

Mesh:

Substances:

Year:  2016        PMID: 26853179     DOI: 10.1016/j.jaad.2015.11.033

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  26 in total

Review 1.  Research gaps in the management and prevention of cutaneous squamous cell carcinoma in organ transplant recipients.

Authors:  M Blomberg; S Y He; C Harwood; S T Arron; S Demehri; A Green; M M Asgari
Journal:  Br J Dermatol       Date:  2017-10-30       Impact factor: 9.302

2.  Spontaneous regression of conjunctival keratoacanthoma.

Authors:  Ghada J AlBayyat; Nandini Venkateswaran; Dan Arreaza; Sander R Dubovy; Anat Galor; Carol L Karp
Journal:  BMJ Case Rep       Date:  2019-07-11

Review 3.  [Surgical treatment of eyelid tumors].

Authors:  M A Varde; B Wiechens
Journal:  HNO       Date:  2018-10       Impact factor: 1.284

4.  Multiple keratoacanthomas arising within red tattoo pigment.

Authors:  Dawn Queen; Lindsey E Richards; Lindsey Bordone; David R Bickers; Sameera Husain; Jesse M Lewin
Journal:  Cutis       Date:  2019-10

5.  Cutaneous Nodules Arranged in a Sporotrichoid Distribution Over the Lower Extremity.

Authors:  Georgia Kyriakou; Eleftheria Vryzaki; Efthymia Gialeli; Sophia Georgiou
Journal:  Dermatol Pract Concept       Date:  2019-12-31

6.  Long-term Change in the Risk of Skin Cancer After Organ Transplantation: A Population-Based Nationwide Cohort Study.

Authors:  Syed Mohammad Husain Rizvi; Bjarte Aagnes; Hallvard Holdaas; Einar Gude; Kristin Muri Boberg; Øystein Bjørtuft; Per Helsing; Torbjørn Leivestad; Bjørn Møller; Petter Gjersvik
Journal:  JAMA Dermatol       Date:  2017-12-01       Impact factor: 10.282

7.  Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy.

Authors:  Azael Freites-Martinez; Bernice Y Kwong; Kerri E Rieger; Daniel G Coit; A Dimitrios Colevas; Mario E Lacouture
Journal:  JAMA Dermatol       Date:  2017-07-01       Impact factor: 10.282

Review 8.  CT and MRI features of scalp lesions.

Authors:  Masaya Kawaguchi; Hiroki Kato; Masayuki Matsuo
Journal:  Radiol Med       Date:  2019-07-03       Impact factor: 3.469

9.  Assessment of Incidence Rate and Risk Factors for Keratoacanthoma Among Residents of Queensland, Australia.

Authors:  Magdalena Claeson; Nirmala Pandeya; Jean-Claude Dusingize; Bridie S Thompson; Adele C Green; Rachel E Neale; Catherine M Olsen; David C Whiteman
Journal:  JAMA Dermatol       Date:  2020-12-01       Impact factor: 10.282

10.  Regression of Periocular Basal Cell Carcinoma: A Report of Four Cases with Clinicopathologic Correlation.

Authors:  Martina C Herwig-Carl; Karin U Loeffler
Journal:  Ocul Oncol Pathol       Date:  2019-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.